Jamie E. Chaft, MD

Articles

Circling the Latest With ctDNA in Lung Cancer

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, discuss the utility with circulating tumor DNA, intriguing data of which were presented during the 2021 ASCO Annual Meeting.

ASCO 2021 Updates With Neoadjuvant Immunotherapy in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, cover the latest results with neoadjuvant immunotherapy strategies that were highlighted at the 2021 ASCO Annual Meeting.

What’s Next in HER2+ and Exon 19 Deletions in NSCLC?

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, recap the 2021 ASCO Annual Meeting and focus on data presented in patients with non–small cell lung cancer that is HER2 positive or harbors an exon 19 deletion.

Enthusiasm With EGFR Exon 20+ in NSCLC

June 28th 2021

Joshua K. Sabari, MD; Jamie Chaft, MD; and Vamsidhar Velcheti, MD, highlight the intriguing data in the realm of EGFR exon 21 insertion mutations in non–small cell lung cancer presented during the 2021 ASCO Annual Meeting.

Kicking Off With KRAS in NSCLC

June 28th 2021

OncLive’s third episode of Thoracic Night Live, a program devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year, focuses on findings presented at the 2021 ASCO Annual Meeting.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Chaft on Predictive Biomarkers in Lung Cancer

July 6th 2020

Jamie E. Chaft, MD, discusses predictive biomarkers in lung cancer.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 10th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Dr. Chaft on Considerations for Restarting Immunotherapy in Lung Cancer

June 9th 2020

Jamie E. Chaft, MD, discusses considerations for restarting immunotherapy in patients with lung cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 21st 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 20th 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Chaft on Immune-Related AEs in NSCLC

May 15th 2020

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Dr. Chaft on the Rise of Immunotherapy in Lung Cancer

February 8th 2020

Jamie E. Chaft, MD, discusses the rise of immunotherapy in lung cancer and research with this treatment modality that is on the horizon.

Dr. Chaft on Investigational Neoadjuvant Immunotherapy Approaches in NSCLC

November 18th 2019

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational neoadjuvant immunotherapy approaches in non–small cell lung cancer (NSCLC).

Dr. Chaft on Ongoing Pivotal Trials in EGFR-Mutant NSCLC

April 19th 2017

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).